Payment overview · 2025
General Payments
$7,492.18
241 reported records · 22 companies
Healthcare provider profile · identity verified
Vicente Separa Ramo, MD
Allopathic & Osteopathic Physicians|Family Medicine · HONOLULU, HI · NPI 1770536443
Verified facts
What the public records show
CMS Open Payments records show Vicente Separa Ramo, MD received $7,492.18 in general payments during 2025 across 241 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 560 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,135.19 | 28.5% | 55 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $684.55 | 9.1% | 28 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $652.28 | 8.7% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $554.65 | 7.4% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $424.98 | 5.7% | 20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $386.15 | 5.2% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $347.94 | 4.6% | 16 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $331.24 | 4.4% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $312.15 | 4.2% | 18 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $251.81 | 3.4% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $208.03 | 2.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $204.36 | 2.7% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $203.31 | 2.7% | 5 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $165.42 | 2.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $151.96 | 2.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $104.08 | 1.4% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.36 | 1.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $82.05 | 1.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.24 | 1.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $68.37 | 0.9% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $45.54 | 0.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.52 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,480.96 | 240 |
| Education | $11.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $946.28 | 20 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $817.36 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $723.17 | 19 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $652.28 | 20 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $473.98 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $365.44 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $350.70 | 13 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $347.94 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $339.90 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $261.15 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $251.81 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $249.60 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $208.03 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $204.36 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $203.31 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $197.86 | 12 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $165.42 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $158.82 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $152.31 | 14 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $151.96 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $147.80 | 2 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.51 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $82.36 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $82.05 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $78.41 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.94 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $51.03 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $50.17 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.74 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $45.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.25 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.00 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $12.04 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 560 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 395 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 146 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 107 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 173 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
29 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
107 | 57 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
86 | 57 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
560 | 186 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
146 | 51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
395 | 157 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
395 | 157 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
173 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1339 | 445 |
| Amlodipine Besylate | Amlodipine Besylate | 1237 | 406 |
| Losartan Potassium | Losartan Potassium | 845 | 284 |
| Telmisartan | Telmisartan | 810 | 246 |
| Metformin Hcl | Metformin Hcl | 738 | 256 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 595 | 197 |
| Farxiga | Dapagliflozin Propanediol | 560 | 186 |
| Metoprolol Succinate | Metoprolol Succinate | 450 | 154 |
| Allopurinol | Allopurinol | 432 | 159 |
| Jardiance | Empagliflozin | 395 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 131 |
| Lisinopril | Lisinopril | 377 | 124 |
| Pravastatin Sodium | Pravastatin Sodium | 334 | 123 |
| Gabapentin | Gabapentin | 330 | 131 |
| Alendronate Sodium | Alendronate Sodium | 311 | 124 |
| Omeprazole | Omeprazole | 283 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 97 |
| Montelukast Sodium | Montelukast Sodium | 256 | 123 |
| Vascepa | Icosapent Ethyl | 250 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 119 |
| Azithromycin | Azithromycin | 212 | 186 |
| Ezetimibe | Ezetimibe | 200 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 193 | 68 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 189 | 61 |
| Tradjenta | Linagliptin | 184 | 45 |
| Irbesartan | Irbesartan | 179 | 57 |
| Meclizine Hcl | Meclizine Hcl | 178 | 102 |
| Rybelsus | Semaglutide | 173 | 56 |
| Famotidine | Famotidine | 163 | 77 |
| Carvedilol | Carvedilol | 153 | 52 |
| Januvia | Sitagliptin Phosphate | 151 | 48 |
| Prednisone | Prednisone | 151 | 122 |
| Kerendia | Finerenone | 146 | 51 |
| Lovastatin | Lovastatin | 143 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 53 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 133 | 59 |
| Celecoxib | Celecoxib | 128 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 37 |
| Furosemide | Furosemide | 119 | 52 |
| Ozempic | Semaglutide | 119 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 118 | 76 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 40 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 112 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 39 |
| Colchicine | Colchicine | 109 | 62 |
| Linzess | Linaclotide | 107 | 57 |
| Nateglinide | Nateglinide | 104 | 32 |
| Alprazolam | Alprazolam | 103 | 28 |
| Simvastatin | Simvastatin | 98 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 97 | 38 |
| Eliquis | Apixaban | 90 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 89 | 26 |
| Prolia | Denosumab | 86 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 35 |
| Felodipine Er | Felodipine | 84 | 26 |
| Finasteride | Finasteride | 82 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 67 |
| Ibandronate Sodium | Ibandronate Sodium | 72 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 31 |
| Edarbi | Azilsartan Medoxomil | 70 | 18 |
| Meloxicam | Meloxicam | 67 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 32 |
| Xarelto | Rivaroxaban | 63 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 40 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 58 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 58 | 21 |
| Valsartan | Valsartan | 58 | 28 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 50 |
| Mupirocin | Mupirocin | 54 | 40 |
| Donepezil Hcl | Donepezil Hcl | 53 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 21 |
| Febuxostat | Febuxostat | 52 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 49 | 30 |
| Colesevelam Hcl | Colesevelam Hcl | 49 | 23 |
| Mounjaro | Tirzepatide | 49 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 30 |
| Fenofibrate | Fenofibrate | 45 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 15 |
| Megestrol Acetate | Megestrol Acetate | 45 | 26 |
| Cephalexin | Cephalexin | 44 | 42 |
| Repaglinide | Repaglinide | 43 | 13 |
| Entresto | Sacubitril/Valsartan | 41 | 15 |
| Desloratadine | Desloratadine | 40 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 35 |
| Nifedipine Er | Nifedipine | 38 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 38 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 16 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Livalo | Pitavastatin Calcium | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 28 |
| Fenofibrate | Fenofibrate,micronized | 35 | 12 |
| Glipizide | Glipizide | 35 | 14 |
| Tramadol Hcl | Tramadol Hcl | 35 | 12 |
| Ibuprofen | Ibuprofen | 33 | 14 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 24 |
| Spironolactone | Spironolactone | 32 | 11 |
| Trulicity | Dulaglutide | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 11 |
| Risedronate Sodium | Risedronate Sodium | 31 | 11 |
| Trazodone Hcl | Trazodone Hcl | 31 | 11 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 30 | 11 |
| Glimepiride | Glimepiride | 30 | 14 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 15 |
| Creon | Lipase/Protease/Amylase | 29 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 11 |
| Fluocinonide | Fluocinonide | 28 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | 21 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 19 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Ofloxacin | Ofloxacin | 19 | 17 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 13 |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,492.18 · 241 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, Livdelzi, M-M-R II, MOUNJARO, NEXLETOL, NUCALA, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PAXLOVID, PROLIA, PURIFIED CORTROPHIN GEL, Prospera, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, Wegovy, ZENPEP, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error